In vitro activity of DR-3355, an optically active ofloxacin
about
In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacinMechanistic study of inhibition of levofloxacin absorption by aluminum hydroxideMechanism of differential activities of ofloxacin enantiomersIn vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosisActivity of levofloxacin in a murine model of tuberculosisLevofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureusIn vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosisSpectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimineScreening and its potential application of lipolytic activity from a marine environment: characterization of a novel esterase from Yarrowia lipolytica CL180.Characterization and its potential application of two esterases derived from the arctic sediment metagenome.Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjectsComparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.Future directions in antimicrobial chemotherapy.In vitro activity of S-ofloxacin.Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method.In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection modelSuggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections.Post-marketing surveillance of the safety of levofloxacin in Japan.Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.Levofloxacin disk potency and tentative interpretive criteria for susceptibility testsLevofloxacin for the treatment of pyelonephritis.Safety and tolerability profile of second-line anti-tuberculosis medications.In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC geneIn vitro activity of HSR-903, a new quinolone.Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous dosesAccumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes.A study on the toxicity of intravitreal levofloxacin in rabbits.
P2860
Q24671010-C1A396F8-938C-4427-8AF6-918C05E7D1C6Q24671290-2579C2B2-266A-4693-9747-ED62631F57FDQ24675769-9CC34B1C-828F-4FB6-BC97-17D56E97941CQ28367763-234D22D3-DE09-40CB-85CF-18E00CE28557Q28369090-23025FA5-ACBA-4709-9AF2-8D56302DB5C4Q28379074-52B33C88-2D8C-4C3C-9BB0-4F12F4C2F65EQ28379137-4F98072D-0BE2-47D8-BF33-62A5403DF6DAQ28379290-6661F24E-C329-4BA0-AFC2-3F480E7D8662Q30828107-B2E5D520-FB10-4CD3-A364-3E0F59402F3FQ33371586-6112F3A7-C59D-455F-ADE8-55FDB88CCEC0Q33753316-18C37E0D-B451-4AA0-89BD-F5BEB2228425Q33979516-3063EB71-C36F-4917-B540-343254EECBC5Q34333286-2E3D1A7E-110A-44C8-8C90-1F7C5704B68EQ35125533-3AB1B089-FA7F-45E0-ACE6-E4D10770536FQ35128473-374D0599-1284-4168-AFA1-AC240EDB6263Q35138146-12D9F1F7-F5F2-4EE8-8861-6CFDE2958360Q35138534-9D25AF7A-1AE6-44BA-B868-678FAC94610EQ35284580-313823E0-89FF-43BA-AD4A-991A35446565Q35530705-06E9AA81-72E0-4065-A750-CC8668CF75D7Q35566524-6FFE9D49-2971-46DD-9408-A898E226C8FDQ35809150-7083BBAD-64F0-4DE1-9561-6CD2EAC84A29Q35812502-D0974EC3-A50E-4FEF-8A2A-CA8C3359AE96Q35822889-4748ED43-0D2B-49A4-AFE8-90E1F2D906B0Q36517253-178D30AE-C68E-4FDD-8C2C-654797D72E74Q36517614-574243A0-F369-4143-B289-5BBFC9D63798Q36649729-BA6A8BF6-E618-49AF-8BB0-EA63379CB88FQ36720778-3F829937-B145-4E50-91AD-091108507C36Q36752886-3D107D1B-F50A-4F91-9099-EEF385F4CC5CQ36753046-B7C5637D-019A-41F0-AB2D-4A2D1FF47825Q37130693-E205E417-7A63-4D4C-ACA3-FE3C7E7303D7Q38101380-9FE175E0-5621-4E30-9192-4427F4C4943BQ38353565-D11D0D66-3D8B-4F19-84F8-8BA0E4F7F4DAQ39557374-D63B82E0-2501-4F65-A1A8-FEF3DFBFB45DQ39557455-2A7B601A-C65B-4B7A-ADD2-D75CE8EFC467Q39781656-B265AE3D-86FD-4FCC-9AA6-84530CDA4E68Q39784355-6A86EB99-D4C1-4A12-B09D-A3CB96C3FAF1Q39784736-4772C270-993F-46B7-9065-8AEE796F5BDBQ39785094-DE5AEF6A-BE46-438E-9540-DA0C92105431Q39866608-9CE618ED-128A-4B3D-ACA1-21A5AF48591BQ40630867-72181ED9-9CFA-4384-9A0D-79BE27BE65CD
P2860
In vitro activity of DR-3355, an optically active ofloxacin
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
In vitro activity of DR-3355, an optically active ofloxacin
@ast
In vitro activity of DR-3355, an optically active ofloxacin
@en
type
label
In vitro activity of DR-3355, an optically active ofloxacin
@ast
In vitro activity of DR-3355, an optically active ofloxacin
@en
prefLabel
In vitro activity of DR-3355, an optically active ofloxacin
@ast
In vitro activity of DR-3355, an optically active ofloxacin
@en
P2093
P2860
P356
P1476
In vitro activity of DR-3355, an optically active ofloxacin
@en
P2093
P2860
P304
P356
10.1128/AAC.32.9.1336
P407
P577
1988-09-01T00:00:00Z